Navigation Links
AstraZeneca and Mental Health Research Institute in Australia Announce Collaboration to Improve Early Detection of Alzheimer's Disease
Date:7/16/2009

LONDON, July 16 /PRNewswire-FirstCall/ -- AstraZeneca and The Mental Health Research Institute in Melbourne, Australia, today announced that they have entered into a research collaboration agreement to develop new ways of identifying Alzheimer's disease patients at early stages of the disease.

Researchers aim to find out whether testing cognition at short intervals (every one to three months) over an eighteen-month period will make it possible to identify individuals just at the point at which they are beginning to suffer cognitive decline as a result of Alzheimer's disease.

The study will be conducted in conjunction with The Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL), which aims to improve understanding of the causes and diagnosis of Alzheimer's disease, and help develop preventative strategies.

Alzheimer's disease is a degenerative brain disease for which there is currently no definitive diagnostic tool. Doctors rely on their clinical judgment to diagnose the disease once it has become symptomatic, but the pathologic process very likely starts a few years beforehand.

Professor Paul Maruff, from the Mental Health Research Institute says, "When assessing cognitive function in an individual at risk for dementia on the first occasion, it is often difficult to determine whether their performance on cognitive tests has declined from some previously higher level. The repeated application of a set of brief and simple cognitive measures could therefore help to identify accurately the point when the onset of Alzheimer's disease was imminent in individual people. This could ultimately lead to a more personalized approach with more effective treatments being given to the right patients at the right time."

Dr Judith Jaeger, Director of Neuroscience Early Clinical Development at AstraZeneca adds, "We recognize that in a
'/>"/>

SOURCE AstraZeneca
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Abbott and AstraZeneca Extend Relationship to Include Co-Promotion of TRILIPIX(R) (fenofibric acid)
2. Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD(TM), an Investigational Treatment for Mixed Dyslipidemia
3. AstraZeneca Studies Show Relief of Nighttime Heartburn and Reduction in GERD-Related Sleep Disturbances
4. Verus Pharmaceuticals Announces a Lawsuit Against AstraZeneca AB and Tika Lakemedel AB
5. Court Grants AstraZeneca Preliminary Injunction Against Apotex in PULMICORT RESPULES Patent Litigation
6. AstraZeneca, the National Alliance for Hispanic Health and LULAC Join Forces to Promote Needed Heart Health Education in Hispanic Communities
7. AstraZeneca Announces TOPROL-XL(R) (Metoprolol Succinate) is Now Available
8. Ingenuity Systems Announces Multi-Year Deal With AstraZeneca
9. Court Grants AstraZeneca Temporary Restraining Order Against Apotex in PULMICORT RESPULES Patent Litigation
10. FDA Advisory Committee Documents for SEROQUEL XR Available on AstraZeneca Web Site
11. AstraZenecas David Brennan Elected PhRMA Board Chairman
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... The University of Houston Graduate College of Social Work is ... $1.25 million grant from the National Institute of Drug Abuse ... the long-term use and health consequences of heroin use. Additionally, ... support future research endeavors. , Heroin use has ... from prescription pain medication abuse to the cheaper and more ...
(Date:8/29/2014)... Lincoln, R.I. (PRWEB) August 29, 2014 A home ... can crop up if unaddressed. That’s why Amica Insurance is sharing ... The National Safety Council suggests taking the following safety measures: , ... and disinfectants – in their original containers, and keep them away ... on a wall bracket near an exit. , Bathroom ...
(Date:8/29/2014)... well-studied neuroregenerative effect, stimulating neurite extension in ... vitro, and enhancing nerve regeneration following nerve ... of FK506 to stimulate nerve regeneration is ... failure and hypertension, and its considerable cost. ... with other drugs reportedly cause life-threatening infections. ...
(Date:8/29/2014)... As a chiropractic physician and medical doctor an ... direct connection between the condition of the feet and ... shoe inserts and orthotics weren’t satisfying my patients, I ... said. , Customizable to a user’s needs, the patent-pending ... in order to help prevent pain in the foot, ...
(Date:8/29/2014)... Aug. 29, 2014 (HealthDay News) -- The main ... the Middle East and North Africa originated in ... studied so-called community-acquired methicillin-resistant Staphylococcus aureus ... have not recently been hospitalized. These infections typically ... person-to-person contact or through touching contaminated objects such ...
Breaking Medicine News(10 mins):Health News:$1.25 million NIH grant to aid research on impact of heroin use 2Health News:Improve Home Safety with Tips from Amica Insurance 2Health News: European MRSA Originated in Sub-Saharan Africa, Study Finds 2
... (OTCBB: GVBP.OB) - GENova Biotherapeutics Inc. ("GENova") today announced ... PLC and unconditionally retract the announcement made earlier this ... Jensen, Chief Science Officer of Bridge BioResearch PLC, will ... , , About GENova Biotherapeutics Inc. , ...
... MISSION VIEJO, Calif., Sept. 18 The Ensign Group, Inc. ... group of skilled nursing, rehabilitative care services and assisted living companies, ... cash dividend of $0.045 per share of Ensign common stock, payable ... of September 30, 2009. Ensign has been a dividend-paying company since ...
... - revenues increase by 21% over ... figures are in Canadian dollars unless otherwise noted), , ... Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today ... 30, 2009. , "We had a very successful year in ...
... HAYWARD, Calif., Sept. 18 Solta Medical, Inc. (Nasdaq: ... market, today announced that it will present at the Maxim Group ... the Grand Hyatt New York Hotel in New York, NY. ... September 29, 2009. Stephen J. Fanning, Chairman, President and Chief ...
... SAN CARLOS, Calif., Sept. 18 Nektar Therapeutics (Nasdaq: ... Global Life Sciences Conference in New York at the Grand Hyatt Hotel ... , The presentation will be accessible via a Webcast through ... Nektar website: http://www.nektar.com . This Webcast will be available ...
... be a nasal spray, followed shortly by injectable one: CDC ... doses of the H1N1 swine flu vaccine will start shipping ... U.S. health officials said Friday. , These first 3.4 million ... FluMist. , "There is a good antibody response to the ...
Cached Medicine News:Health News:Bioniche Reports Fiscal 2009 Year-End Results 2Health News:Bioniche Reports Fiscal 2009 Year-End Results 3Health News:Bioniche Reports Fiscal 2009 Year-End Results 4Health News:Bioniche Reports Fiscal 2009 Year-End Results 5Health News:Bioniche Reports Fiscal 2009 Year-End Results 6Health News:Bioniche Reports Fiscal 2009 Year-End Results 7Health News:Bioniche Reports Fiscal 2009 Year-End Results 8Health News:Bioniche Reports Fiscal 2009 Year-End Results 9Health News:Bioniche Reports Fiscal 2009 Year-End Results 10Health News:Bioniche Reports Fiscal 2009 Year-End Results 11Health News:Bioniche Reports Fiscal 2009 Year-End Results 12Health News:Bioniche Reports Fiscal 2009 Year-End Results 13Health News:Bioniche Reports Fiscal 2009 Year-End Results 14Health News:Bioniche Reports Fiscal 2009 Year-End Results 15Health News:Solta Medical to Present at the Maxim Group Growth Conference 2Health News:Nektar Therapeutics to Present at the UBS 2009 Global Life Sciences Conference in New York City 2Health News:1st Doses of Swine Flu Vaccine Set for Early October 2Health News:1st Doses of Swine Flu Vaccine Set for Early October 3Health News:1st Doses of Swine Flu Vaccine Set for Early October 4
(Date:8/28/2014)... NEW YORK , Aug. 28, 2014 /PRNewswire/ ... report is available in its catalogue: ... http://www.reportlinker.com/p02343464/North-America-Laparoscopes-Market-Outlook-to-2020.html North ... GlobalData,s new report, "North America Laparoscopes Market ... the North America Laparoscopes market. The report provides ...
(Date:8/28/2014)... -- CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – ... - http://photos.prnewswire.com/prnh/20140828/140879 ) The ... Poland " an essential source of information and ... and provides insights into the demographic, regulatory, reimbursement ... provides valuable insights into the trends and segmentation ...
(Date:8/28/2014)... , Aug. 28, 2014 Tianyin ... ), a pharmaceutical company that specializes in patented ... and active pharmaceutical ingredients (API) today updates the ... Qionglai Facility (QLF). The Company ... (GMP) dataset for China Food & Drug Administration,s ...
Breaking Medicine Technology:North America Laparoscopes Market Outlook to 2020 2North America Laparoscopes Market Outlook to 2020 3North America Laparoscopes Market Outlook to 2020 4North America Laparoscopes Market Outlook to 2020 5North America Laparoscopes Market Outlook to 2020 6North America Laparoscopes Market Outlook to 2020 7North America Laparoscopes Market Outlook to 2020 8North America Laparoscopes Market Outlook to 2020 9North America Laparoscopes Market Outlook to 2020 10North America Laparoscopes Market Outlook to 2020 11Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 2Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 3Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 4Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 5TPI Submits Dataset for GMP Inspection at Qionglai Facility (QLF) 2
... Some of the world,s largest pharmaceutical firms announced this ... in order to slash costs and keep investors happy, exposing ... AstraZeneca were the first to announce further job cuts with ... has already seen an extraordinary amount of job cuts over ...
... Md., Feb. 29, 2012  MedImmune today announced that ... approved FluMist® Quadrivalent (Influenza Vaccine Live, Intranasal) for ... early in the second quarter of last year.  ... approved by the FDA. All other ...
Cached Medicine Technology:Job Cuts from Major Pharmaceutical Firms Results in Tougher Competition, Says Advance Recruitment 2MedImmune Announces FDA Approval of First Four-strain Flu Vaccine, FluMist® Quadrivalent (Influenza Vaccine Live, Intranasal) 2MedImmune Announces FDA Approval of First Four-strain Flu Vaccine, FluMist® Quadrivalent (Influenza Vaccine Live, Intranasal) 3
... These specialty Eraser instruments have been ... with the right tool for situations ... a series of 25 gauge intraocular, ... discrete treatment of target tissues for ...
... to over 2,000 medical clinics nation wide, ... in mind, ChartingPlus relies heavily on a ... to improve documentation quality and increase productivity ... medical content is specific to your medical ...
Transfer your exams to AltaPoint with our EMR Exam Word Lists. Document systems as normal and annotate exceptions to the systems in the exam. AltaPoint EMR is configured to allow a specialty to cust...
... Pro Software developed a touchscreen EHR and ... While a user can choose to use ... to maintain eye contact while recording encounter ... Pro EHR also runs on a pen ...
Medicine Products: